Skip to main content
Premium Trial:

Request an Annual Quote

ArcticDx Licenses Colorectal Cancer Biomarker IP from UK's CRT

NEW YORK (GenomeWeb News) – Cancer Research Technology, the technology commercialization arm of Cancer Research UK, said today that it will license certain intellectual property related to colorectal cancer risk assessment to the molecular diagnostics company ArcticDx.
Under the non-exclusive license agreement, ArcticDx will pay CRT an upfront payment and royalties from any sales of the biomarker-based test it plans to develop using the technology.
The test, called Colo Risk, is being developed to identify people who may be at higher risk for bowel cancer. ArcticDx CEO Greg Hines said the saliva-based test should be commercially available by the end of 2008.
The agreement will allow “some results” from Cancer Research UK-funded genome-wide association studies to be integrated into Colo Risk, CRT said, adding that these studies were “the first” to identify common SNPs that increase bowel cancer risk.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.